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ABSTRACT
Johne’s disease (JD), or paratuberculosis, is a chronic 
enteric disease of ruminants, caused by infection with 
Mycobacterium avium ssp. paratuberculosis (MAP). 
Johne’s disease causes considerable economic losses 
to the US dairy industry, estimated to be over $200 
million annually. Available control strategies include 
management measures to improve calf hygiene, test-
and-cull strategies, and vaccination. Although the first 
2 strategies have shown to reduce the prevalence of 
MAP, they require dedicated and long-term efforts from 
dairy producers, with often relatively slow progress. As 
a result, uptake of both strategies has not been as wide 
as expected given the economic benefits especially of 
improved hygiene. Vaccination has also been found to 
reduce the prevalence and economic losses of JD, but 
most economic estimates have been based on simula-
tion of hypothetical vaccines. In addition, if an animal 
is vaccinated, cross-reactivity between MAP antibodies 
and bovine tuberculosis (BTB) antigens may occur, de-
creasing the specificity of BTB tests. Therefore, MAP 
vaccination would cause additional indirect costs to the 
BTB surveillance and control program. The objective 
of the present study was to use data from a MAP vac-
cine trial together with an epidemiologic and economic 
model to estimate the direct on-farm benefits of MAP 
vaccination and to estimate the indirect costs of MAP 
vaccination due to the cross-reactivity with BTB tests. 
Direct economic benefits of MAP vaccination were es-
timated at $8.03 (90% predictive interval: −$25.97 to 
$41.36) per adult animal per year, all accruing to the 
dairy producers. This estimate is likely an underestima-
tion of the true direct benefits of MAP vaccination. In 
addition, indirect economic costs due to cross-reactivity 
were $2.14 per adult animal per year, making MAP 
vaccination economically attractive. Only in regions or 
states with a high frequency of BTB testing (because 
of, for example, Mycobacterium bovis outbreaks in a 
wild deer population) and areas where typically small 
groups of animals are BTB tested would MAP vaccina-
tion not be economically attractive.
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INTRODUCTION
Johne’s disease (JD), or paratuberculosis, is a 
chronic enteric disease of cattle and other ruminants 
infected by Mycobacterium avium ssp. paratuberculosis 
(MAP). In the dairy industry, JD is important due 
to the farm-level economic losses it causes (Ott et al., 
1999). In addition, although not proven, there is con-
cern about the potential causal role of MAP in Crohn’s 
disease in humans [National Research Council (NRC) 
Committee on Diagnosis and Control of Johne’s Dis-
ease, 2003]. Several measures are available to control 
the spread of MAP on dairy farms including test-and-
cull, management changes, and vaccination [National 
Research Council (NRC) Committee on Diagnosis and 
Control of Johne’s Disease, 2003]. However, because of 
the low sensitivity of diagnostic tests for MAP, strate-
gies based on test-and-cull alone are not effective in 
reducing its prevalence (Groenendaal et al., 2003; Dor-
shorst et al., 2006). In addition, the costs of test-and-
cull strategies tend to be higher than their economic 
benefits (Groenendaal et al., 2003; Kudahl et al., 2007). 
Improved calf management practices tend to be more 
effective in reducing the incidence of infection (Espejo 
et al., 2014) and within-herd MAP prevalence (Collins 
et al., 2010; Radia et al., 2013), and the farm-economic 
benefits of improving management practices have been 
estimated higher than their costs (Groenendaal et al., 
2003; Dorshorst et al., 2006).
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A combination of test-and-cull strategies and man-
agement practices is often recommended to reduce the 
prevalence of MAP, while simultaneously making it 
economically attractive to the producer (Groenendaal 
et al., 2003; Dorshorst et al., 2006). The challenge with 
this combined strategy, however, is that it takes consid-
erable resources and long-term efforts before seeing a 
benefit. Adoption of these control strategies by produc-
ers has therefore been limited.
Vaccination against MAP requires less effort by 
producers, and field studies that have evaluated MAP 
vaccination on MAP-infected herds have generally 
concluded that it effectively reduces fecal shedding of 
MAP (Knust et al., 2013) and the number of clinical 
JD cases, and that it can be cost-efficient at the herd 
level for high-prevalence herds (van Schaik et al., 1996). 
Simulation studies to evaluate the effectiveness of vac-
cination against MAP and its economic consequences 
have made similar conclusions but were often based on 
hypothetical (“potential”) assumptions about the ef-
fectiveness of MAP vaccines (Groenendaal et al., 2003; 
Cho et al., 2012; Lu et al., 2013). Moreover, an impor-
tant drawback of MAP vaccination is that it can inter-
fere with the diagnosis of bovine tuberculosis (BTB) 
and therefore with BTB eradication and surveillance 
programs. Vaccination causes a greater percentage of 
false-positive BTB tests to occur in MAP-vaccinated 
animals (i.e., MAP vaccination lowers the specificity of 
the BTB tests), resulting in higher costs due to addi-
tional tuberculosis testing costs, and losses due to more 
herd quarantines. Dressler et al. (2010) examined the 
economic effects of this cross-reactivity and found that 
the benefits of vaccination exceed the costs of Johne’s 
cross-reactivity. However, their study was based on an 
estimate of the benefits of MAP vaccination in herds 
with a very high MAP prevalence. In addition, they as-
sumed a herd that is located within a geographic region 
with a tuberculosis outbreak attributed to surrounding 
endemically infected wild deer population.
To our knowledge, no empirical study has simulta-
neously considered the economics of MAP vaccination 
and its economic consequences on the BTB surveillance 
and eradication program. The objective of the current 
study was 2-fold. First, the study used a previously 
developed empirically based simulation model of MAP 
vaccination on dairy herds (Zagmutt et al., 2012) to 
estimate the direct farm-economic consequences of 
MAP vaccination. Second, the study compared these 
direct farm-economic effects of MAP vaccination with 
its indirect economic effect on the BTB surveillance 
program. The paper provides decision support for pro-
ducers and policy-makers regarding the economics of 
MAP vaccination based on empirical data.
MATERIALS AND METHODS
Cost-Benefit Analysis and Overall  
Modeling Approach
To achieve our objectives, 3 main steps were taken:
 1.  First, using a previously developed epidemiologic 
stochastic Markov Chain simulation model (Zag-
mutt et al., 2012) that was based on empirical 
data from a vaccination field trial (Knust et al., 
2013), the direct farm-economic costs and ben-
efits of MAP vaccination were estimated.
 2.  Second, the indirect costs of MAP vaccination to 
the BTB surveillance and eradication program 
due to cross-reactivity of MAP vaccinates with 
the caudal-fold tuberculin (CFT) and the com-
parative cervical tuberculin (CCT) tests were 
calculated.
 3.  Third, a cost-benefit analysis and a comprehen-
sive sensitivity (break-even) analysis were per-
formed to understand under what circumstances 
and assumptions MAP vaccination is economi-
cally attractive when taking into account its ef-
fects on the BTB program.
In all steps of the economic analysis, only the mar-
ginal costs and benefits due to MAP vaccination were 
considered. Table 1 provides an overview of the main 
costs and benefits taken into account in the cost-benefit 
analysis.
The default perspective of economic analysis is the 
society’s perspective, disregarding which stakehold-
ers accrue the different costs and benefits. However, 
Table 1. Overview of main costs and benefits of Mycobacterium avium ssp. paratuberculosis (MAP) vaccination, how they are estimated, and 
payers or beneficiaries
Direct or indirect Costs or benefit Estimation approach/method Payer or beneficiary
Direct Costs of vaccine Calculated in the MAP simulation model Producers
Direct Benefits due to the reduction of 
Johne’s disease losses
Calculated in the MAP simulation model Producers
Indirect Costs to the bovine tuberculosis 
surveillance program
Separate analysis Costs to producers and to state 
or federal government
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because not all costs and benefits accrue to the same 
stakeholders, an economic analysis was also performed 
separately, from both the producer’s perspective and 
from the taxpayer’s perspective.
Direct Farm-Level Economic Effects  
of MAP Vaccination
A previously developed Markov Chain model and its 
parameter estimates (Zagmutt et al., 2012) were used 
to estimate the within-herd epidemiological effects 
of MAP vaccination. In short, the model included 7 
MAP-infection or disease states: (1) susceptible, (2) 
nonshedder adult, (3) latent, (4) low shedder, (5) heavy 
shedder, (6) clinical, and (7) culled. The main data set 
used (described by Knust et al., 2009, 2013) was from 
a 6-yr longitudinal data set of a controlled clinical trial 
on 3 MAP-infected Wisconsin (WI) dairy herds (A, B, 
C). Herd size ranged from 325 to 825 cows and, before 
participation in the trial, annual culling losses attribut-
able to clinical JD within the 3 herds were about 6 to 
8%. For the first 10-mo period of the trial, every other 
heifer calf born in each herd was administered a killed 
MAP vaccine, ensuring similar exposure for vaccinated 
and nonvaccinated cattle from a given herd. After this 
period, all heifer calves subsequently born within the 3 
herds were vaccinated. During the study period, addi-
tions were made to the 3 herds. Despite recommenda-
tions to only purchase animals from tested sources, the 
cattle added to herds were from untested or unknown 
sources. The data set used in this study contained 5 yr 
of survival and testing data for the 162 vaccinated and 
145 control (i.e., nonvaccinated) heifers enrolled during 
the first 10 mo of the study. Fecal samples from all 
vaccinated and control animals were collected before 
each calving and at culling, independent of reason, over 
a period of 7 yr.
With the 6-yr longitudinal data set and using a 
latent-class Bayesian model, JD diagnostic test param-
eters were estimated, which were then used to simulate 
a longitudinal MAP infection trajectory for each vacci-
nated and control animal (Zagmutt et al., 2012; Espejo 
et al., 2015). The disease trajectories were subsequently 
used to estimate the joint uncertainty distributions of 
the transition probabilities of the stochastic Markov 
Chain model. The transition probabilities were then 
used to project the annual expected progression of 
MAP within the herd over 20 yr (Zagmutt et al., 2012). 
To determine the effect of MAP vaccination on the 
spread of MAP within the herd, the annual within-herd 
spread parameters (i.e., transition probabilities) were 
estimated separately for vaccinated and unvaccinated 
animals in the 3 herds. For an overall assessment of 
the effect of vaccination, the within-herd MAP spread 
parameters of the 3 herds were weighted equally. Given 
the industry-level perspective of the current study, only 
parameter uncertainty was considered and no random-
ness was included in the spread of MAP within indi-
vidual herds.
Given the very low prevalence of BTB within the 
United States (i.e., the current surveillance efforts de-
tect a 0.0002% BTB prevalence with 95% confidence; 
USDA-APHIS-VS, 2009), and because >90% of US 
dairy operations have cattle infected with MAP (Lom-
bard et al., 2013), the analysis’ perspective was of a 
BTB-free and MAP-infected herd with a true MAP 
prevalence of 10% of shedding animals (low and heavy 
shedders and clinical animals). To show the effect of 
the within-herd prevalence at the start of vaccination, 
the model was also run using within-herd prevalences 
ranging from 5 to 35% with increments of 5% (based on 
Raizman et al., 2011).
The direct costs of MAP vaccination were calculated 
within the MAP infection simulation model by multi-
plying the costs of vaccination (assumed at $12/heifer 
calf, based on discussions between author E. A. Patton 
and private practitioners in WI) by the number of new 
heifer calves each annual time-step within the MAP 
simulation model.
The direct net benefits of MAP vaccination were 
defined as the difference in losses between the situa-
tions with vaccination and without vaccination (i.e., 
the reduction of losses because of vaccination), also 
taking into account the costs of vaccination. Losses in 
either of the 2 situations were estimated by simulating 
the expected within-herd MAP infection dynamics over 
a 20-yr period and attributing different losses to the 
different MAP infection statuses. The direct benefits 
of MAP vaccination were then evaluated by comparing 
losses (and vaccination costs) in the 2 situations.
Table 2 shows the 3 types of direct losses due to 
MAP-infected animals that were included within the 
model: (1) The reduction in 305-d milk production of 
MAP-infected animals was based on the reduction in 
milk production described by Groenendaal and Wolf 
(2008). A milk price of $0.44/kg ($20/100 lb.) was 
assumed (NASS, 2014). (2) The loss due to a lower 
slaughter value of animals with clinical JD was as-
sumed at $353 (Groenendaal and Wolf (2008), adjusted 
for inflation to 2014). (3) The third category of losses 
of JD included was caused by suboptimal (premature) 
culling of MAP-infected animals (Groenendaal et al., 
2004). For each culled and infected animal, the loss 
due to suboptimal culling was set equal to the differ-
ence in retention pay-off value of the animal with and 
without the JD-related reduction in milk production. 
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The retention pay-off value of an animal is the expected 
profit from keeping the cow compared with immediate 
replacement and thus represents the loss due to subop-
timal culling.
To calculate the total losses due to JD for the herd, 
the losses per animal were multiplied by the number of 
infected animals (in the 7 different infection statuses) 
and the number of culled infected animals as simulated 
by the MAP infection transmission model. The total 
annual net direct benefits due to MAP vaccination 
were subsequently calculated as the losses due to JD in 
the nonvaccination (NV) scenario minus the losses due 
to JD in the vaccination (V) scenario, minus the costs 
of MAP vaccination.
All total annual direct benefits were discounted at 
a 5% annual discount rate to calculate the net present 
value (NPV). Net present value is a standard method 
for the financial appraisal of long-term projects and is 
used widely in economics (Brealey and Myers, 2007). 
Within an NPV, all net benefits over time (i.e., both 
costs and benefits) are discounted back to the start of 
the first year of the investment (in this situation, the 
first year of the 20-yr simulation) to account for the 
time-value of money and the riskiness of the investment 
decision. The assumed discount rate of 5% is higher 
than the risk-free rate but lower than discount rates 
generally used in other economic sectors. Finally, all 
NPV (calculated at the herd level over a 20-yr period) 
were subsequently converted to their equivalent annual 
value per animal. Monte Carlo simulation using 10,000 
iterations was performed using the ModelRisk software, 
version 5.1.0.3 (Vose Software, Ghent, Belgium).
Indirect Effects of MAP Vaccination
The indirect effects of MAP vaccination were defined 
as all costs due to additional false-positive diagnostic 
tests (because of cross-reactivity between MAP vac-
cination and BTB tests) within the current US BTB 
program (USDA-APHIS, 2004). Although accredited 
veterinarians and approved state or federal veterinar-
ians have some discretion on which approved BTB 
diagnostic tests to use, we assumed the commonly used 
protocol, in which a full-herd CFT test was performed 
first, followed up by CCT test of all CFT responders 
and histopathology of all CCT reactors after euthaniz-
ing the CCT-positive animals. No effect of MAP vacci-
nation on the BTB slaughter surveillance was assumed 
because histology, PCR, and culture are used as the 
default test, which is not known to be affected by MAP 
vaccination.
The total annual expected indirect costs per animal 
due to MAP vaccination were calculated as the sum of 
the costs to producers and to the (state and federal) 
government:
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where Ptest = annual probability an animal is CFT test-
ed within the BTB surveillance program; Pextra(CFT+ 
> 0) = P(CFT+ > 0|V) – P(CFT+ > 0|NV); that 
is, the additional probability of at least 1 CFT+ due 
to vaccination; Pextra(CCT+ > 0) = P(CCT+ > 0|V) 
– P(CCT+ > 0|NV); that is, the additional prob-
ability of at least 1 CCT+ due to vaccination; n = 
number of animals CFT tested per testing round; CR 
rateCFT = (SpCFT – SpCFT|V), the CFT cross-reactivity 
rate; CR rateCCT = (SpCCT – SpCCT|V), the CCT cross-
reactivity rate; SpCFT = specificity of CFT test; SpCFT|V 
= specificity of CFT test for MAP-vaccinated animal; 
SpCCT = specificity of CCT test; SpCCT|V = specificity 
of CCT test for MAP-vaccinated animals; CCFT-POS = 
cost of an additional CCT test; CCCT-POS = costs of 
removal and histopathology, PCR, and culture of an 
additional CCT-positive animal; CQUAR-PROD1,2 = cost of 
Table 2. Overview of direct losses due to Johne’s disease (JD) included in the economic analysis
Description of loss Economic effect Source
Milk production reduction $96 to $436/animal per year, depending on disease status Groenendaal and Wolf, 2008
Lower slaughter value $361 per culled JD clinical animal Groenendaal and Wolf, 2008, inflated to 2014
Suboptimal culling $192 to $570 per culled infected animal Groenendaal et al., 2004, updated
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a quarantine period to producer after (1) at least one 
CFT-positive or (2) at least one CCT-positive animal; 
CQUAR-GOVT1,2  = cost of a quarantine period to govern-
ment after (1) at least one CFT-positive or (2) at least 
one CCT-positive animal. An overview of parameter 
values related to all indirect costs of MAP vaccination 
is shown in Table 3.
Within the US BTB program, only a fraction of all 
adult animals within the United States are tested each 
year. The probability that a random animal is BTB 
tested per year (Ptest) as part of the BTB surveillance 
program varies with (among others) the M. bovis status 
of the state and the location of the herd. Assuming that 
all animals within a region or state are equally likely 
to be tested, Ptest is the percentage of animals within 
a region or state that is BTB tested with a CFT test 
antemortem per year. In 2007, the percentage of cattle 
CFT tested within all US accredited-free states was 
2.87%; therefore, Ptest was set at 2.87% per animal per 
year (USDA-APHIS-VS, 2009). The Ptest within states 
ranged from 0.04% (Alaska) and 0.23% (Montana) to 
34.39% (Rhode Island) and 34.52% (Arizona).
The specificity of the CCT test (SpCCT) used in this 
study is conditional on a false-positive CFT test result 
(Farnham et al., 2012). The reported SpCFT test varies 
greatly as illustrated by Farnham et al. (2012), who, in 
their meta-analysis, reported values ranging from 89.2 
to 98.8% (weighted mean: 92.55%). Also, MAP vac-
cination increases the number of false-positive results 
of the CFT (i.e., it reduces the specificity of the CFT 
test), as shown by Lima et al. (2012).
The costs per additional CFT-positive test 
(CCFT-POS) were assumed to be $4.41 per animal based 
on Dressler et al. (2010). Regarding the costs due to an 
additional CCT positive test (CCCT-POS), we assumed 
that CCT-positive animals would be slaughtered and 
histopathology performed (in practice, PCR and culture 
are also performed in certain situations). Indemnity 
depends on the value of the animal and was set at the 
maximum USDA indemnity value of $3,000 per animal. 
Costs of histopathology to the state were assumed at 
$354 per animal (USAHA, 2004; inflated to 2013).
The probability of at least one CFT+ animal, 
P(CFT+ > 0), is calculated as follows:
P(CFT+ > 0) = 1 − SpCFT
n,
where SpCFT = specificity of the CFT test, and n = 
number of animals tested per herd per testing round; 
P(CFT+ > 0) was calculated separately for vaccinated 
and nonvaccinated herds, and the difference of the 
2 probabilities was equal to Pextra(CFT+ > 0). This 
extra probability of quarantine of a herd due to cross-
reactivity of MAP vaccination with the CFT test is 
then multiplied by the costs of quarantine due to a 
CFT+ animal. The probability of at least one CCT+ 
animal [P(CCT+ > 0|V) and P(CCT+ > 0|NV) for 
vaccinated and nonvaccinated herds, respectively] was 
calculated as follows:
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where SpCCT = specificity of the CCT test, and n = num-
ber of animals tested per herd per testing round, and 
all other terms are as defined previously; P(CCT+ > 
0) was calculated separately for vaccinated and nonvac-
cinated herds, and the difference of the 2 probabilities 
was equal to Pextra(CCT+ > 0). This extra probability 
of quarantine of a herd due to cross-reactivity of MAP 
vaccination with the CCT test was then multiplied by 
the costs of quarantine due to a CCT+ animal.
The total costs of a potential quarantine of a herd, 
during which no animals can leave the farm, due to 
Table 3. Overview of parameter values used to calculate the indirect costs of Mycobacterium avium ssp. paratuberculosis vaccination 
Parameter Description1 Default Source
Ptest Annual probability of CFT testing an animal in bovine 
tuberculosis program
2.87% USDA-APHIS-VS, 2009
n Number of animals tested per herd per testing round 300 —
SpCFT Specificity of CFT test 92.55% Farnham et al., 2012
SpCFT|V Specificity of CFT test, vaccinated animal 70% Lima et al., 2012; Larsen et al., 1978
SpCCT Specificity of CCT test 98.19% Farnham et al., 2012
SpCCT|V Specificity of CCT test, vaccinated animal 90% Lima et al., 2012; Larsen et al., 1978
CCFT-POS Government costs because of additional CFT positive test $4.41 Dressler et al., 2010
CCCT-POS Government costs because of additional CCT positive test $3,354 USDA-APHIS, 2004; Dressler et al., 2010
CQUAR-GOVT1,2 Government costs because of quarantine after either CFT+ 
or CCT+
$1,234 Dressler et al., 2010
CQUAR-PROD1 Producer costs because of quarantine after CFT+ $1,191 Dressler et al., 2010
CQUAR-PROD2 Producer costs because of quarantine after CCT+ $3,929 Dressler et al., 2010
1CFT = caudal-fold tuberculin; CCT = comparative cervical tuberculin.
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MAP vaccination were assumed to be $2,425 ($1,234 
+ $1,191) and $5,163 ($1,234 + $3,929) for the first 
CFT+ and CCT+ animal, respectively.
Cost-Benefit Break-Even Analysis
The annual direct benefits of MAP vaccination per 
animal per year were compared with the indirect an-
nual costs per animal per year due to cross-reactivity 
within the BTB surveillance program. Vaccination for 
MAP was considered economically attractive if the di-
rect benefits of MAP vaccination were larger than the 
indirect costs.
Because the main parameters related to this cost-
benefit analysis are either uncertain or can vary be-
tween geographical areas within the United States, an 
extensive sensitivity analysis was performed to calcu-
late the value of each of these input variables where the 
total indirect costs equal the total direct benefits. This 
sensitivity analysis therefore provides the combination 
of break-even parameters at which vaccination switched 
from economically attractive to economically unattract-
ive and vice versa. The 7 parameters examined in this 
break-even analysis included (1) the direct net benefits 
of vaccination, (2) Ptest, (3) SpCFT|V, (4) SpCCT|V, (5) 
CQUAR-PROD1, (5) CQUAR-PROD2, and (6) n. Because the 
estimated annual direct benefits of MAP vaccination 
were based on disease-spread characteristics for only 3 
WI dairy herds, all break-even analyses were conducted 
with 1 of the 2 varying parameters being the annual 
direct benefits of MAP vaccination. In addition to the 
direct benefits of MAP vaccination found within this 
study, the estimated direct benefits of MAP vaccina-
tion from van Schaik et al. (1996) and Groenendaal and 
Galligan (2003) are also displayed within each of the 
break-even analyses.
Related to SpCFT|V and SpCCT|V, the actual specificity 
of either the CFT or CCT test is not important per 
se, but what is relevant is how the specificities are de-
creased because of MAP vaccination (i.e., the difference 
in specificity of either test for a MAP vaccinate and a 
MAP nonvaccinate). Therefore, in the break-even anal-
ysis, only the specificities of the CFT and CCT tests in 
MAP vaccinates were varied and not those in nonvac-
cinates. With regard to CQUAR-PROD1 and CQUAR-PROD2, 
both costs can vary greatly between states, production 
systems, and individual producers and were therefore 
examined within the break-even analysis.
In the default analysis, we assumed the commonly 
used protocol, in which a full-herd CFT test (herd of 
300 adult animals) was performed. However, in certain 
states and situations smaller groups of animals are also 
CFT tested. Therefore, n (number of animals tested 
per herd per testing round) was also varied in the 
break-even analysis.
Microsoft Excel’s Solver, version 2010 (Microsoft 
Corp., Redmond, WA) was used to identify the 
break-even points, where direct benefits are equal 
to indirect costs, for all 7 parameters. The economic 
model that compares the direct economic benefits 
of MAP vaccination and the indirect economic 
costs is available at http://www.epixanalytics.com/
downloads/Paratuberculosis/TB-JDVaccinationCost-
BenefitAnalysis09-29-2014.xlsm.
RESULTS
Direct Effects of MAP Vaccination
Starting vaccination at a 10% within-herd prevalence, 
the expected forecasted within-herd prevalence without 
and with vaccination after 5 yr was, respectively, 11.5% 
[95% predicted interval (PI): 7.0 to 16.3%] and 9.2% 
(95% PI: 4.9 to 14.3%; Figure 1).
Five and 10 yr after start of the vaccination, the 
expected effect of vaccination (i.e., difference between 
V and NV scenarios) was a decrease in within-herd 
prevalence of 2.3% (95% PI: −4.2 to 8.7%) and 2.9% 
(95% PI: −5.4 to 11.0%), respectively.
When simulating individual herds, the expected 
number of infected animals during the first 5 yr from 
the start of the vaccination decreased in the 3 herds 
by 2.5, 21.9, and 9.6% (overall 11.4% decrease) due 
to MAP vaccination (Table 4). The expected decrease 
of heavy shedders and clinical animals was greater on 
the 3 farms by 23.6, 24.2, and 3.4%, respectively, and 
17.0% overall.
Three years after starting vaccination at 10% within-
herd prevalence, the expected annual net direct ben-
efits per year became positive and increased until 5 to 
7 yr after the start of vaccination to approximately $12 
per animal per year (Figure 2). Expected net direct 
benefits of vaccination plateaued after about 5 to 7 yr, 
when the difference in within-herd prevalences of the V 
versus NV strategies stabilized (Figure 1). The effect of 
the MAP vaccination on direct MAP losses increased 
because it takes multiple years for vaccinated calves to 
because adult animals and thus for vaccination to have 
an effect on direct MAP losses.
Discounting back all net direct benefits of MAP vac-
cination, the expected annualized direct net benefits 
were estimated at $8.03 per adult animal (90% PI: 
−$25.97 to $41.36). For herds A, B, and C, the direct 
benefits were estimated at $7.05 (90% PI: −$31.63 to 
$46.44), $13.23 (90% PI: −$14.13 to $41.40), and $4.13 
(90% PI: −$26.16 to $33.71), respectively (Table 5). 
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Herd B had the highest forecasted reduction in total 
infected animals and highest expected benefits. Herd 
C’s reduction in losses was forecasted to be relatively 
limited, mostly because of a limited decrease in the 
number of high shedders and animals with clinical JD 
(i.e., the animals that cause the highest losses).
The expected direct benefits of MAP vaccination per 
animal per year increase when the prevalence at the 
start of the vaccination program is higher (Figure 3). 
Expected direct benefits of MAP vaccination increase 
from $7.00 to $10.93 per animal and year with an in-
crease of the start prevalence of MAP shedders from 5 
to 25%.
Indirect Effects of MAP Vaccination
Two important parameters when calculating the 
indirect costs of MAP vaccination are the additional 
probabilities (due to MAP vaccination) of a quarantine 
due to a CFT+ or CCT+ animal, Pextra(CFT+ > 0) 
and Pextra(CCT+ > 0), respectively. Both parameters 
and P(CCT+ > 0) and P(CFT+ > 0) for vaccinated 
and nonvaccinated animals are shown in Figure 4 in 
relation to the number of animals that are CFT tested 
(n) within a herd; CCT testing is conditional on CFT 
testing (i.e., when finding a CFT+ animal).
Figure 4 shows that when CFT testing groups of ani-
mals between 1 and 30, the difference between P(CFT+ 
> 0|NV) and P(CFT+ > 0|V) ranges between 10 and 
50%, whereas with groups of 30 animals and larger, 
the difference quickly reaches 0%. Therefore, if CFT 
tests within the BTB are typically performed on larger 
groups of animals, MAP vaccination could have no or 
very little effect on the probability of at least one false-
positive CFT test, whereas with smaller group sizes the 
effect can be considerable.
Furthermore, the difference between P(CCT+ > 
0|NV) and P(CCT+ > 0|V) does reach a maximum 
Figure 1. Within-herd prevalence of Mycobacterium avium ssp. paratuberculosis (MAP)-shedding animals (i.e., low shedders, heavy shedders, 
and clinical animals in the model) starting at 10% within-herd prevalence without vaccination (control) and with vaccination (vaccine). P5 and 
P95 = 5th and 95th percentiles, respectively.
Table 4. Mean (%) and 90% predicted interval (PI) range of the forecasted percentage change in the number of latent infected, low shedders, 
heavy shedders, and clinical animals due to vaccination in the first 5 yr after starting Mycobacterium avium ssp. paratuberculosis vaccination
Herd Total infected Latent infected Low shedders Heavy shedders and clinical
A Mean −2.5 −5.0 13.8 −23.6
Range −22.1 to 19 −27.3 to 19 −18 to 48.3 −43.4 to −2.7
B Mean −21.9 −19.1 −23.9 −24.2
Range −36.2 to −6.9 −37.6 to 0.6 −40.9 to −6.1 −43.1 to −6
C Mean −9.6 −9.6 −8.6 −3.4
Range −26.3 to 8.9 −29.1 to 13.5 −30.7 to 15.6 −30.8 to 25.3
Overall Mean −11.4 −11.4 −6.2 −17.0
Range −30.9 to 10.5 −32.3 to 13 −33.9 to 27.3 −40.7 to 10.2
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when CFT testing groups of around 100 animals at 
a time, and the difference continues to be large even 
with much larger group sizes. Therefore, in contrast to 
Pextra(CFT+ > 0), across a wide range of group sizes, 
MAP vaccination considerably increases Pextra(CCT+ 
> 0), the probability of at least one CCT-positive ani-
mal.
Using the default values from Table 3, the expected 
indirect costs of MAP vaccination on the BTB pro-
gram were calculated at $0.25 at the herd level and 
$1.89 at the government level, for a total of $2.14 per 
animal per year. These indirect costs are lower than 
the direct benefits of MAP vaccination, indicating that 
MAP vaccination from an overall societal perspective is 
economically attractive. Taking into account different 
economic perspectives, at the herd level, the expected 
net benefits are $7.77 ($8.02 − 0.25) per animal per 
year, whereas at the government level, the net benefits 
are −$1.89 per animal per year.
Cost-Benefit Break-Even Analysis
The estimated annual direct benefits of MAP vac-
cination and the proportion of animals CFT tested per 
year (Ptest) both have an effect on the overall economic 
attractiveness of MAP vaccination (Figure 5A). Figure 
5A shows that vaccination is not economically attrac-
tive for herds in regions or states in which Ptest is high, 
because of a higher probability, for example, of a tuber-
culosis outbreak. It also shows that if the expected net 
direct benefits of MAP vaccination were higher than 
estimated in the current study, vaccination would also 
be economically attractive in areas with a higher Ptest.
Figure 2. Mean annual net direct benefits of Mycobacterium avium ssp. paratuberculosis (MAP) vaccination, including 90% predictive inter-
val (PI) over 20-yr period, assuming 10% prevalence at start of vaccination. P5 and P95 = 5th and 95th percentiles, respectively.
Table 5. Mean, 5th percentile (P5) and 95th percentile (P95) of direct 
net benefits of vaccination per adult animal per year, starting at a 10% 
within-herd Mycobacterium avium ssp. paratuberculosis prevalence of 
shedders
Herd Mean P5 P95
A $7.05 −$31.63 $46.44
B $13.23 −$14.13 $41.40
C $4.13 −$26.16 $33.71
Overall $8.03 −$25.97 $41.36
Figure 3. Expected net direct benefits of Mycobacterium avium 
ssp. paratuberculosis (MAP) vaccination per animal per year, assum-
ing different within-herd animal prevalence levels of shedders at start 
of vaccination.
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Second, the estimated annual direct benefits of MAP 
vaccination and the specificity of the CFT test for 
MAP vaccinates were varied (while keeping all other 
parameter at their default values, see Table 3). Figure 
5B shows that even if the specificity of the CFT for 
MAP vaccinates were only 50% (versus the assumed 
specificity of MAP nonvaccinates of 92.55%), vaccina-
tion would still be economically attractive at current 
tuberculosis testing rates.
Third, the break-even analysis with varying annual 
direct benefits of MAP vaccination and specificity of 
the CCT test for MAP vaccinates shows that when 
the specificity of the CCT for vaccination is 70% or 
less and annual direct benefits of MAP vaccination 
are around $7/animal, vaccination becomes economi-
cally unattractive (Figure 5C). Under the default 90% 
specificity of the CCT test for MAP vaccinates, direct 
MAP vaccination benefits could be as low as $2/animal 
per year to get to the break-even point where direct 
benefits become equal to indirect costs.
The break-even analysis on the annual direct ben-
efits of MAP vaccination and costs to the producers 
of a farm standstill because of a CFT-positive animal 
(CQUAR-PROD1) shows that in the default situation what-
ever CQUAR-PROD1, MAP vaccination direct benefits 
exceed indirect costs. The reason for this is that with 
CFT testing of 300 nonvaccinates, the probability of a 
standstill because of at least one CFT-positive animal 
[P(CFT+ > 0|NV] would already be close to 100% 
(see Figure 4); therefore, vaccination could not further 
increase this probability, reducing to a negligible level 
the marginal effect of MAP vaccination on quarantines 
because of a CFT-positive animal. Therefore, an al-
ternative break-even analysis was performed on the 
annual direct benefits of MAP vaccination and costs to 
the producers of a farm standstill because of a CFT-
positive animal (CQUAR-PROD1), but with n = 10 to rep-
resent situations or states where animals are typically 
CFT tested in smaller groups (Figure 5D). Figure 5D 
shows that using MAP vaccination direct benefits from 
the current studies ($8.02/animal per year) and with 
n = 10, overall vaccination is economically marginally 
unattractive. With slightly higher direct MAP vacci-
nation benefits, lower quarantine costs (or when n > 
11, see Figure 5F), vaccination direct benefits exceed 
vaccination indirect costs.
Figure 4. Probability of at least one false-positive caudal-fold tuberculin (CFT) [P(CFT+ > 0)] or comparative cervical tuberculin (CCT) 
[P(CCT+ > 0)] test when testing a vaccinated (V) or nonvaccinated (NV) group of animals. Extra P is the difference between the probability 
for a vaccinated and nonvaccinated group.
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The break-even analysis on the annual direct ben-
efits of MAP vaccination and costs to the producers 
of a farm standstill because of a CCT-positive animal 
(CQUAR-PROD2) shows that even if CQUAR-PROD2 is well 
over $3,929, vaccination is economically attractive 
(Figure 5E).
Finally, based on the break-even analysis with vary-
ing annual direct benefits of MAP vaccination and 
varying number of animals CFT tested per testing 
round, MAP vaccination becomes economically indif-
ferent when animals are CFT tested in groups of 11 or 
smaller (Figure 5F).
Figure 5. Break-even analysis of Mycobacterium avium ssp. paratuberculosis (MAP) vaccination with varying annual direct benefits of vac-
cination per animal, and varying (A) proportions of animals caudal-fold tuberculin (CFT) tested per year (Ptest), (B) specificity of CFT test for 
MAP-vaccinates (SpCFT|V), (C) specificity of comparative cervical tuberculin (CCT) test for MAP-vaccinates (SpCCT|V), (D) costs to the produc-
ers of a farm standstill because of a CFT-positive animal (CQUAR-PROD1) with n = 10, (E) costs to the producers of a farm standstill because of 
a CCT-positive animal (CQUAR-PROD2), and (F) number of animals CFT tested per testing-round (n). Any point in the gray area represents situ-
ations in which MAP vaccination is not economically attractive, whereas any point in the white area represents situations in which the benefits 
of vaccination are higher than the costs. Squares () represent direct MAP vaccination benefits estimates from the current study, triangles () 
represent direct benefits from Groenendaal and Galligan (2003), and circles () represent direct benefits from van Schaik et al. (1996), inflated 
to 2014 as per Dressler at al. (2010). AF = accredited-free.
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DISCUSSION
Direct Benefits of MAP Vaccination
The present economic analysis shows that the ex-
pected direct benefits of MAP vaccination are positive, 
primarily as a result of vaccination reducing the fre-
quency of heavy shedders and clinical animals within 
vaccinated herds. Expected net direct benefits per 
animal per year were $8.02 for a herd with an initial 
10% prevalence of MAP-shedding animals. The results 
also show that the effect of MAP vaccination on the 
overall prevalence and the prevalence of latent infected 
and low shedder animals is fairly small, whereas the 
effect on the number of heavy shedders and clinical ani-
mals is larger, which is consistent with earlier studies 
(Groenendaal and Galligan, 2003; Knust et al., 2013; 
Tewari et al., 2014).
Given the limited disease transmission data available 
from the 3 WI dairy herds, there is considerable un-
certainty (90% PI from −$25.97 to $41.36/animal per 
year) regarding the net direct benefits of MAP vaccina-
tion presented in this study. Collecting additional data 
could reduce this parameter uncertainty, and therefore 
can provide decision-makers with greater confidence 
in their optimal decisions. A value-of-information 
analysis, similar to those performed in human health 
cost-effectiveness analysis, could help determine the 
value to decision-makers of collecting such additional 
information (Briggs et al., 2012).
When interpreting the results of the direct benefits 
of MAP vaccination, the following limitations and 
assumptions are important to consider. First, the 
disease-spread parameters of the epidemiological model 
were estimated based on only 3 WI dairy herds, and 
therefore the epidemiologic and economic predictions 
and results may not be applicable to other types of 
US dairies. Second, the disease-spread parameters (e.g., 
transition probabilities) of the stochastic Markov Chain 
model were estimated separately for vaccinated and 
the nonvaccinated animals within the same herds. The 
study design (Knust et al., 2013), where vaccinates and 
controls were systematically allocated within a farm, 
minimized the effect of differences in management 
practices between animals of the same herd. However, 
Knust et al. (2013) noted that farmers were not blind 
to the status of animals within their herd, which may 
have influenced some of the practices applied to vac-
cinated versus nonvaccinated animals. Then, as fewer 
vaccinated animals shed and did so at lower levels 
compared with the controls, vaccination of half of the 
herd likely had an effect beyond the protection of the 
vaccinated animals themselves and reduced the number 
of infections between nonvaccinated control animals in 
the study. In addition, before the start of the study, 
all cows were tested with an ELISA and in 2 of the 
3 herds only heifer calves from ELISA-negative dams 
were retained in the herd during the duration of the 
study. Because the current study results depend on the 
difference between disease spread in controls and vac-
cinated animals, the results presented in the current 
paper therefore likely represent an underestimation of 
the true effect of vaccination that would result from 
the vaccination of all animals within a herd. On the 
other hand, the analysis by Knust et al. (2013) did 
not separate the effect of vaccination from the effect 
of management practices, which also help in limiting 
disease spread and contribute to the apparent effect of 
vaccination. In the study by Tewari et al. (2014), MAP 
vaccination decreased the prevalence and shedding, 
even in a herd that implemented virtually no change 
in preventive practices, supporting the conclusion that 
vaccination by itself has an effect on prevalence and 
shedding, but prevalence may be further decreased by 
implementation of good management practices. Third, 
the disease-spread model developed by Zagmutt et al. 
(2012) and used in this study was a Markov Chain 
model and thus assumed that infection probability 
did not decrease as the number of shedding animals 
decreased over time. Consequently, both the reduction 
of within-herd JD prevalence due to MAP vaccination 
and its economic effects are likely underestimations of 
the true direct benefits of vaccination. Two sensitivity 
analyses were performed, in which the MAP infection 
probability decreased an additional 50 and 100%, re-
spectively, over the simulated 20-yr timeframe (i.e., this 
was a reduction beyond the one-time reduction seen 
during the 6 yr of the MAP vaccination field trial on 
the WI dairy herds). Net expected direct benefits of 
MAP vaccination in both situations increased to $17.47 
and $28.90/animal per year, respectively (results not 
shown).
The expected net direct benefits found in this study 
were generally lower than in previous studies (Figure 6). 
van Schaik et al. (1996) reported net direct benefits of 
$54.42 and $29.14 per cow for herds with 11 and 5% of 
cows showing clinical JD at the start of vaccination, re-
spectively (1996 estimates inflated to 2014 according to 
Dressler et al., 2010). Both situations imply a very high 
overall MAP prevalence and therefore, their estimates 
of the economic benefits of MAP infections are not rep-
resentative of the typical MAP prevalence in a US herd. 
In addition, van Schaik et al. (1996) attributed the full 
reduction of the losses to vaccination, whereas some 
of the effects may have been due to improved hygiene 
management. On the farms used for disease-spread data 
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in the current study, controls and vaccinated animals 
were subject to the same management and therefore 
the difference between the 2 groups was the net effect 
of vaccination. In another study, Groenendaal and Gal-
ligan (2003) estimated that the net direct benefits range 
from $1.07 to $20.28 (average of $10.34) per animal per 
year, depending on the assumed (hypothetical) vaccine 
efficacy (2003 prices inflated to 2014). Their estimates 
seem consistent with the current results, as the lat-
ter are likely an underestimate of the true direct MAP 
vaccination benefits. In a third study, Cho et al. (2012) 
found the maximum costs per vaccination dose (i.e., 
the reduction of losses due to the vaccine) of either a 
low efficacy or high efficacy vaccine for 10% prevalence 
herds to be $103 or $223, respectively, compared with 
no control measure being implemented, and −$102 
and $17, respectively, when vaccination was compared 
with an improved hygiene and test-and-cull strategy. 
Assuming 43 vaccinated heifer calves per 100 cows per 
year and a cost of the vaccine of $12, this suggests 
direct annual benefits of MAP vaccination per animal 
per year of $39 and $91 without other control measures 
implemented and −$49 and $2 when vaccination was 
compared with an improved hygiene and test-and-cull 
strategy. Focusing on losses due to JD only (i.e., not 
on the effects of vaccination on JD losses), Ott et al. 
(1999) standardized the losses per animal and year due 
to JD from 6 studies and estimated them to range from 
$31 to $42, whereas Groenendaal and Galligan (2003) 
estimated losses at $48 (both expressed in 2014 prices). 
Given that (1) vaccines do not prevent all JD losses, (2) 
it takes a few years before benefits start, and (3) there 
are costs of MAP vaccination, we believe that the true 
expected net direct annual benefits of MAP vaccination 
are most likely less than $25 to $30 per animal, depend-
ing on the initial herd prevalence. Given these previous 
studies, given that the currently calculated benefits of 
$8.02 from the current study are likely underestimated, 
and given the sensitivity analysis around the reduction 
of infection probability, the realistic range around the 
true expected direct benefits of MAP vaccination prob-
ably lies in the range of $10 to $25 per animal per year.
The current study shows that the direct benefits of 
MAP vaccination increase only slightly with a higher 
MAP prevalence at the start of the vaccination, which 
is consistent with Cho et al. (2012). For example (Fig-
ure 3), there is only a 56% increase of economic benefits 
of vaccination when increasing the starting prevalence 
by 500% (i.e., from 5 to 25%). This is because both 
in the current study and in Cho et al. (2012) without 
vaccination, the prevalence is assumed to increase over 
time and therefore the overall expected economic ben-
efits of vaccination are not directly proportional to the 
starting prevalence.
Figure 6. Comparison of the estimates of the direct benefits of Mycobacterium avium ssp. paratuberculosis (MAP) vaccination per animal 
per year between different studies. Vaccine efficacy from Cho et al. (2012) and from Groenendaal and Galligan (2003) were hypothetical and 
the lower and upper ends of the ranges indicate benefits with a low- and high-efficacy hypothetical vaccine, respectively. Vaccine efficacy in van 
Schaik et al. (1996) and the current study were based on field data. The lower and upper ends of the range of van Schaik et al. (1996) indicate 
a 5% and 11% prevalence of Johne’s disease clinical cases, respectively. The lower and upper end of the range of the current study indicates the 
10th and 90th percentiles (P10 and P90) of the predictive interval (PI) around the triangular, which are the expected direct benefits.
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Indirect Effects of MAP Vaccination
Our overall cost-benefit analysis shows that for a 
typical US dairy herd (e.g., a MAP-infected herd that 
is not located within a region where there is a high 
probability of CFT testing because of, for example, 
tuberculosis infections), the indirect costs of MAP vac-
cination are smaller than the direct benefits of vaccina-
tion, and therefore MAP vaccination is economically 
attractive. All direct benefits of MAP vaccination ac-
crue to producers, whereas the majority of the indirect 
costs are paid for by the government or taxpayers.
Cost-Benefit Break-Even Analysis
The aim of cost-benefit break-even analysis was to 
show under what circumstances MAP vaccination is 
economically attractive or not, considering both direct 
and indirect costs and benefits. Seven main inputs were 
varied to assess their effect on the economically pre-
ferred strategy.
In general, when varying the main inputs of the cost-
benefit analysis, vaccination still has greater direct 
benefits than indirect costs. There are, however, a few 
exceptions to this.
As shown in Figure 5A, for regions where a high 
percentage of all animals are CFT tested each year 
(e.g., 34.52% in Arizona in 2007), vaccination is not 
economically attractive. Herd-wide CFT testing is typi-
cally due to the presence of local M. bovis infections 
and therefore vaccination is economically not attrac-
tive in regions or states that have a high likelihood of 
tuberculosis infections. As shown in Figure 5F, if the 
number of animals CFT tested/herd is 11 or lower and 
MAP vaccination direct benefits are $8.03, vaccination 
becomes economically unattractive. Our current study 
assumed by default that animals are CFT tested within 
large groups (i.e., whole-herd tests), but in situations or 
states where this is typically not the case the indirect 
costs of MAP vaccination increase and therefore MAP 
vaccination overall becomes less attractive. Therefore, 
we believe that, in most circumstances, the expected 
total economic benefits of MAP vaccination outweigh 
the indirect expected economic costs.
All break-even analyses were presented from an 
overall economic perspective (i.e., combining all costs 
and benefits together). All direct benefits from MAP 
vaccination accrue to producers while the majority 
of the indirect costs are incurred by both producers 
and the government. From a government or taxpayer 
perspective, MAP vaccination is not attractive as it 
always only causes additional costs. When considering 
only the producers’ perspective and ignoring indirect 
costs at the government level, the expected indirect 
costs of MAP vaccination are reduced considerably and 
therefore MAP vaccination becomes economically more 
attractive. In addition, as calculated in a break-even 
analysis that considers only the producer-level direct 
benefits and indirect costs of MAP vaccination (results 
not shown), MAP vaccination continues to be economi-
cally attractive under a wider variety of scenarios, in-
cluding scenarios with CFT testing of smaller groups 
of animals. However, this does not mean that for every 
individual producer, actual direct MAP vaccination 
benefits are higher than actual indirect costs.
Dressler et al. (2010) also studied the cross-reactivity 
of MAP vaccination while considering the indirect costs 
to the BTB program. However, they used $53.03 per 
animal per year as the direct benefits of MAP vac-
cination, which was based on van Schaik et al. (1996), 
a study that considered herds with a very high JD 
prevalence (11% animals with clinical JD at start of 
vaccination). Moreover, Dressler et al.’s (2010) perspec-
tive was of a dairy herd in a geographic region given a 
BTB outbreak attributed to surrounding endemically 
infected wild deer population. Their estimate of the in-
direct costs of MAP vaccination due to cross-reactivity 
ranged from $30.78 to $32.72 per cow per year, which 
is considerably higher than the $2.14 per animal per 
year estimated in the current study. This difference was 
mainly due to their assumption of a tuberculosis out-
break in the region. In this study, in contrast, given the 
very low prevalence of BTB within the United States, 
the default probability of a random bovine being CFT 
tested per year (because of, for example, a tuberculo-
sis outbreak in the region) was assumed to be 2.87% 
(USDA-APHIS-VS, 2009).
In the current study, the default situation was CFT 
testing at the herd level. However, as shown in Figures 
4 and 5F, when the number of animals that are CFT 
tested per testing round is smaller, the marginal indirect 
costs of MAP vaccination per animal and year due to 
cross-reactivity increase considerably. The main reason 
for this is that if individual animals or smaller groups 
of animals are CFT tested, there will be more instances 
(i.e., a higher probability) where cross-reactivity causes 
the first CFT- or CCT-positive animal, which results 
in costs due to a standstill on the farm at the producer 
level and additional testing costs at the government 
level.
This current study assumed an interference between 
MAP vaccination and BTB testing, as supported by 
several studies (Köhler et al., 2001; Lima et al., 2012; 
Thomsen et al., 2012). Although other studies reported 
no cross-reactivity (Coad et al., 2013; Tewari et al., 
2014), they were based on other vaccines or types of 
BTB tests (i.e., serological tests vs. cell-based tests). In 
addition, the current study only took into account ad-
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ditional false-positive test results (i.e., cross-reactivity) 
of MAP vaccinates but did not consider potential ad-
ditional positive results from MAP-infected animals. 
Field observations (E. A. Patton) suggest there may be 
some cross-reactivity of MAP infection with CFT tests, 
but Lima et al. (2012) found no significant differences 
in the CFT response rate between MAP-infected and 
noninfected animals. If MAP infection actually caused 
cross-reactivity with either the CFT or CCT tests, the 
indirect costs of vaccination would be less than pre-
sented in this study because vaccination does decrease 
the MAP prevalence.
CONCLUSIONS
First, the benefits of MAP vaccination were estimated 
to be positive, at $8.03 per animal per year, on average. 
This likely represents an underestimation of the true 
direct benefits of MAP vaccination in MAP-infected 
herds. Second, in most circumstances, the expected 
direct benefits of MAP vaccination were higher than 
the expected indirect costs of vaccination due to cross-
reactivity within the BTB program, resulting in posi-
tive total net benefits. Third, as shown in an extensive 
break-even analysis, for producers in a region or state 
with a high probability of CFT testing, the indirect 
costs will increase and may exceed the direct benefits 
of MAP vaccination. An important consideration with 
the current conclusions is that all net direct benefits are 
incurred by producers, whereas the indirect costs are 
mostly paid for by the government or taxpayer. Over-
all, our study indicated that vaccination against JD is 
an economically attractive tool on MAP-infected dairy 
herds in regions with limited CFT testing. Vaccination 
for MAP would become even more economically at-
tractive if MAP vaccines or BTB serological tests that 
minimize cross-reactivity were to become available.
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